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ABSTRACT
Objectives: Indigenous medicines are widely used throughout Africa, despite a lack of
scientific evidence for their safety or efficacy. The aims of this study were: (a) to conduct a pilot
study of the safety of a common indigenous South African phytotherapy, Lessertia frutescens
(Sutherlandia), in healthy adults; and (b) to contribute to establishing procedures for ethical and
scientifically rigorous clinical trials of African indigenous medicines.
Design: A randomized, double-blind, placebo-controlled trial of Sutherlandia leaf powder in
healthy adults.
Setting: Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, South Africa.
Participants: 25 adults who provided informed consent and had no known significant
diseases or allergic conditions nor clinically abnormal laboratory blood profiles during
screening.
Intervention: 12 participants randomized to a treatment arm consumed 400 mg capsules of
Sutherlandia leaf powder twice daily (800 mg/d). 13 individuals randomized to the control arm
consumed a placebo capsule. Each participant received 180 capsules for the trial duration of 3
mo.
Outcome Measures: The primary endpoint was frequency of adverse events; secondary
endpoints were changes in physical, vital, blood, and biomarker indices.
Results: There were no significant differences in general adverse events or physical, vital,
blood, and biomarker indices between the treatment and placebo groups (p . 0.05). However,
participants consuming Sutherlandia reported improved appetite compared to those in the
placebo group (p¼0.01). Although the treatment group exhibited a lower respiration rate (p ,
0.04) and higher platelet count (p ¼ 0.03), MCH (p ¼ 0.01), MCHC (p ¼ 0.02), total protein (p ¼
0.03), and albumin (p ¼ 0.03), than the placebo group, these differences remained within the
normal physiological range, and were not clinically relevant. The Sutherlandia biomarker
canavanine was undetectable in participant plasma.
Conclusion: Consumption of 800 mg/d Sutherlandia leaf powder capsules for 3 mo was
tolerated by healthy adults.
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PLoS CLINICAL TRIALSINTRODUCTION
The vast majority of people in South Africa use traditional
medicines, which the government has recently recognized as
an integral part of the public health system. However, there
have been no scientiﬁc studies of traditional medicines to
evaluate their safety and efﬁcacy, nor is there agreement as to
the ethical and regulatory norms for the conduct of clinical
trials of such phytotherapies.
Infusions and stem and leaf decoctions of the indigenous
South African plant Lessertia frutescens (L.) Goldblatt & J. C.
Manning (syn. Sutherlandia frutescens [L.] R. Br.), commonly
called Sutherlandia, have been widely used in South Africa as
traditional medicines since they were ﬁrst adopted by the
Khoi, San, and Nama peoples. In fact, the traditional Tswana
name ‘‘Phetola’’ means ‘‘it changes’’ many illnesses into
favorable outcomes. More speciﬁcally, it is taken to treat
symptoms associated with AIDS [1–3], and to combat cancer
[4–6], infections [7], inﬂammation [8,9], and stress [10].
A study in vervet monkeys (Chlorocebus aethiops) found that
up to nine times the advertised dose of Sutherlandia (81 mg/kg
body weight per day for 3 mo) resulted in no signiﬁcant
changes to relevant haematological, biochemical, and phys-
iological parameters [11]. The present investigation aimed to
(a) monitor adverse events in healthy human participants; (b)
monitor changes in physical, vital, blood, and biomarker
indices; (c) contribute to establishing procedures for the
ethical and scientiﬁc conduct of a human clinical trial of a
traditional medicine.
Objective
Our objective was to conduct a pilot study of the safety of
Sutherlandia leaf powder capsules in healthy adults.
METHODS
Participants
The study took place at Tiervlei Trial Centre, Karl Bremer
Hospital, Bellville, South Africa. Forty-one adults were
recruited and screened from August to September 2004.
Participant inclusion criteria were body weights within 25%
of an appropriate body mass index and no signiﬁcant diseases
or clinically signiﬁcant abnormal laboratory values during
screening. Participants had no history of allergic conditions
(asthma, urticaria, eczema; autoimmune disorders), systemic
lupus erythematosis; dyspepsia, gastric ulcer, or duodenal
ulcer; or psychiatric disorders. Their 12-lead ECGs had no
signiﬁcant abnormalities. They were not on regular medical
treatment, and did not take any medication 14 d prior to the
study. They had a smoking history or less than ten pack-years,
no recent history of alcoholism (.2 y) or consumption of
alcohol within 48 h of receiving study medication, and did not
use any recreational drugs or have a history of drug
addiction. Female participants were tested and found not to
be pregnant, and all women were requested to use appro-
priate means of contraception. Participants who did not meet
the aforementioned criteria were excluded from the study.
All participants were able to communicate effectively with
study personnel, were informed of the nature of the study,
and provided informed consent.
The study protocol (protocol number M03/11/06) was
approved by the Stellenbosch University Institutional Re-
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Editorial Commentary
Background: In Africa, traditional herbal medicines are given for many
illnesses. In particular, one herbal medicine, Sutherlandia (Lessertia
frutescens) is commonly given in the belief that this herb will treat some
of the symptoms associated with HIV/AIDS, such as nausea and lack of
appetite, amongst others. However, there is very little evidence relating
to the safety and none to the efficacy of this herb. Generally, when new
drugs are developed, the first stage of human testing involves a Phase 1
trial. This type of trial would typically involve small numbers of healthy
individuals, who would receive progressively increasing doses of the
drug under study, and would be closely monitored for any sign of side
effects. Phase 1 trials would typically also collect data from blood
samples to find out how the drug is handled in the body and broken
down and eliminated. Therefore, the researchers here carried out a
preliminary study to assess just the safety of Sutherlandia. 25 healthy
adults were randomized to receive either tablets containing a fixed dose
of Sutherlandia leaf powder daily for three months, or matched placebo
tablets containing lettuce leaf powder, for the same period of time. The
main aim of the trial was to assess safety, so the primary outcomes were
adverse events experienced by the participants. The researchers also
measured standard outcomes such as blood pressure, heart rate, body
weight, urine glucose, protein, and many others, at one-month intervals
over the three-month period.
What the trial shows: Adverse events experienced by trial participants
over the three months of this trial included those that might be expected
in a group of otherwise healthy individuals, such as headaches, insomnia,
allergies, malaise, palpitations, nosebleeds, and so on. The researchers
did not see statistically significant differences between treatment and
placebo groups in any of the major categories of these events. Most
physical and laboratory measurements also showed no statistically
significant differences between the study groups. However, there were
statistically significant, but small, differences between groups in
respiratory rate and in various basic blood tests. The researchers did not
think these differences were clinically important. Overall, this trial
suggested that Sutherlandia use was not associated with side effects at
this dosage and over this time scale.
Strengths and limitations: Strengths of this study include the use of
randomization to distribute individuals to either the Sutherlandia or
control groups, and in the use of a placebo control group, which
therefore allowed the researchers to compare the frequencies of adverse
events in the Sutherlandia group with what might be expected among
healthy individuals over the course of three months. An important
limitation is the small sample size of the trial. This size limits the
sensitivity of the trial to detect rare adverse events to the herb under
study, and therefore one cannot say conclusively that the herb is safe,
based on this data. Additionally, the study looked only at the
participants’ response to one dosage level of Sutherlandia. A strategy
using progressively increasing doses would have allowed the researchers
to see if there was a maximum tolerated dose to this herb. A further
limitation in this study is the lack of data relating to how the herb is
broken down in the body; these data are normally an important part of
Phase 1 trials and, combined with safety data, are crucial to finding out
whether a compound is safe when given at a dosage that allows it to be
available to the appropriate tissues.
Contribution to the evidence: Data from previous studies in nonhuman
primates have shown that Sutherlandia is not associated with toxic or
other side effects at approximately equivalent or higher doses than that
normally taken by people with HIV/AIDS. This study adds safety data
relating to Sutherlandia consumption in healthy humans, which confirm
the primate data. However, it is crucial to collect more data relating to
how the probable active ingredients of Sutherlandia are absorbed and
broken down, and to assess safety at different dosages, before studies
are even considered for the next stage, which is to see whether
Sutherlandia has any efficacy in people with HIV/AIDS.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.search Board (IRB) on 10 March 2004 with assurances to
provide amendments to the board regarding any changes to
the protocol, report unexpected serious adverse events or
adverse drug reactions suspected to be related to the study
drug, notify in the event the study was discontinued, adhere
to the principles of informed consent for all participants
(providing patient information and consents in English,
Afrikaans, and Xhosa languages), and provide progress
reports twice each year during the trial. The protocol was
also approved by the South African Medicine Control
Council (MCC protocol number TICIPS001) on 20 July
2004, with assurances that sufﬁcient amounts of product of
assayed quality to conduct the trial was available, and to
notify the MCC of any severe adverse events or if the trial was
discontinued, provide progress reports during the trial, and
to administer the medicine under the direction of an
authorized trialist. To ensure medical coverage for potential
harm of the individuals from participation in the study trial,
the trial was underwritten by a national (South African)
insurance company as a requirement by both the Stellen-
bosch IRB and MCC. Application materials, including the
protocol, were provided to the University of Missouri Health
Sciences IRB, reviewed and approved on 7 April 2004 (project
number 1042077) for conduct of activities in South Africa as
approved by the local Stellenbosch IRB and South African
MCC reviewing agencies.
Interventions
Of the 41 participants, 25 who met the trial criteria were
enrolled in the study and randomized to two groups (Figure
1): 12 randomized to a treatment arm consumed capsules
containing 400 mg of Sutherlandia leaf powder (400 mg of
plant material per capsule; 600 lg of canavanine per capsule)
twice daily (800 mg/day) and 13 randomized to the control
arm consumed a placebo capsule of lettuce leaf powder twice
per day. The treatment and placebo materials were placed in
rapidly releasing capsules, and these were assessed pharma-
ceutically for content uniformity, stability, and release
characteristics as well as microbial, heavy metal, and pesticide
contamination, before the products were packaged and used
in the 3-mo clinical trial. Furthermore, the clinical trial
conformed to MCC and NCCAM guidance on the quality of
biologically active ingredients and placebo materials used in
complementary, alternative, and traditional medicine prod-
ucts.
Outcomes
The primary endpoints of this study were incidence (number)
and type of adverse events recorded during the treatment
period.
The secondary endpoints were: (a) changes in weight, blood
pressure, heart rate, respiratory rate, body temperature from
baseline to end of treatment; and (b) changes in haemato-
logical and biochemical parameters from baseline to end of
treatment.
Sample Size
In the absence of previous data, a convenience sample size of
about 12 participants per treatment group was chosen for
this ﬁrst study of a South African traditional medicine in
healthy humans. This relatively small sample size is a
limitation of the study. It does, however, give sufﬁcient
power to detect an effect size of 1.20 with 80% power based
on doing a two-sample t-test at a signiﬁcance level of 0.05
with a two-sided alternative. Effect size is deﬁned as the
difference in group means divided by the standard deviation
of the response variable under consideration. This applies to
numeric variables. For categorical variables, the numbers are
too small to do meaningful tests.
Randomization: Sequence Generation
To achieve randomization, a list of random numbers
allocating to the two treatments (A, active treatment; B,
placebo) a maximum of 13 participants per group was
generated using a GraphPad Software (http://www.graphpad.
com) calculator option. For each number, a 3-mo supply of
the relevant treatment (active or placebo) was labeled with
that particular number. The randomized number generation
and labeling of the treatments were performed by one person
at the School of Pharmacy, University of the Western Cape,
and the labeled materials (for 3-mo dosing of each of 25
participants) shipped to the clinical trial site.
Randomization: Allocation Concealment
The person generating the randomized list also did the
labeling of the treatments and kept the randomized list.
Randomization: Implementation
At the trial site, participants were sequentially allocated to
the treatments in the order in which they were recruited, i.e.,
the ﬁrst person who qualiﬁed for inclusion was given
treatment number 1, the second one treatment number 2,
and so on. When allocated, the participant ID number was
added to the label details on the capsule containers. The
clinician on site made this allocation.
Figure 1. Trial Profile
CONSORT flowchart
doi:10.1371/journal.pctr.0020016.g001
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The placebo and treatment capsules containing plant
materials were packed in identical nontransparent contain-
ers. Neither the participants nor the clinicians knew which
treatment they received or dispensed. The data collected
were retrieved from the case report form by another
researcher, at the South African Herbal Science and
Medicine Institute, the University of the Western Cape, who
loaded it into a database. Once accuracy of the data was
conﬁrmed (i.e., clean ﬁle status), the database was forwarded
to the statisticians who, only at this time, were supplied with
the randomized treatment list. The statisticians then identi-
ﬁed the participants allocated to each treatment.
Laboratory Measurements and Blood Sampling
Participants were provided with diaries in which to self-
report all adverse events for the duration of the trial.
Participants were screened (at the baseline visit, participants
were screened for physical, vital, haematological, biochem-
ical, and endocrine indices), randomized (at postbaseline,
participants were provided with capsules containing either
Sutherlandia or placebo material), treated, and assessed (at
months 1–3) for the same parameters that were determined at
the baseline visit. Participants were subjected to a physical
examination (weight, blood pressure, heart rate, respiratory
rate, body temperature, and ECG measurement), and they
provided blood samples for haematology, endocrine, and
biochemistry analysis by standard laboratory methods. The
plasma samples of trial participants were analyzed for
canavanine by liquid chromatographic separation and mass
spectrophotometric determination, with a Waters API Q-
TOF Ultima LCMSMS system (http://www.waters.com). Other
biochemical variables were measured with Abbott AxSYM
(http://www.abbottdiagnostics.com) and Beckman Coulter
CX9 ALX (http://www.beckmancoulter.com) systems, respec-
tively. All haematology indices were measured using a
Beckman Coulter Gen-S system, while CD3, CD4, and CD8
counts were determined by ﬂow cytometry, with a Beckman
Coulter EPICS system.
Statistical Methods
Analysis for adverse events was done descriptively. With the
small number of participants in each group the power to
detect all but very large differences is relatively small. Doing
Chi-square tests and ﬁnding that results are insigniﬁcant
would not be very informative. Consequently, the number of
participants who experienced adverse events of different
types is given. Some participants reported the same adverse
event (e.g., ‘‘increased appetite’’) on more than one occasion.
For this reason we counted the number of participants who
experienced an adverse event at least once for the summary
rather than giving a count of the number of times the event
was reported. Counts, proportions, and 95% conﬁdence
intervals for the proportions are given.
For the statistical analysis of all the haematology and
biochemistry parameters, a repeated measures ANOVA
model was used, with the treatment group as one factor and
PREPOST, an indicator for the post-treatment measurement,
as a factor with repeated measures. The interaction term
(treatment by PREPOST) measures the difference between
the comparison of Sutherlandia (treatment) versus placebo
groups at PRE (baseline) and the comparison of Sutherlandia
versus placebo groups at POST (months 1–3: treatment). The
Kenward-Roger denominator degrees of freedom method
was used for the ﬁxed effects testing, whilst Proc Mixed in
SAS Version 9.1 (http://www.sas.com) was used for the
modelling. Least squares means were used to estimate
treatment effects at the combined visits 3–5 based on the
mean response models. Comparisons between pretreatment
and post-treatment were obtained for all indices in the study.
Statistical signiﬁcance for these outcomes was set at the 5%
level. Again, in the spirit of being conservative, adjustments
for multiple tests (such as the Bonferroni adjustment) were
not made. This most likely resulted in some false positives.
RESULTS
Recruitment and Participant Flow
A total of 41 participants were recruited and screened (visit 1:
baseline physical, vital, and blood indices) between August
and September 2004. Of these, 25 consented, met the trial
criteria, and were subjected to a blood draw for haematology,
endocrine and biochemistry analysis, to establish baseline
(pretreatment) values. Thereafter, they were randomized
(postbaseline) to receive treatment capsules (n ¼ 12) or
placebo control capsules (n ¼ 13) that contained a small
amount of dried lettuce leaves twice per day, treated, and
assessed (at months 1–3). Participants were given a diary to
record the times they took their trial medication, adverse
effects they may have experienced, and other medications
they may have taken over the course of the trial. During the
three-month study period, one adult was lost to follow-up and
another withdrew from the treatment group. In the placebo
group, two adults withdrew and another became pregnant.
Baseline Data
Baseline data for vital, physical, haematological, biochemical,
and endocrine indices were similar for the 25 eligible
participants (Table 1).
Outcomes and Estimation
In summarising the adverse events reported by participants at
any of the follow-up visits, we note that one individual in the
placebo group was only in the study for 5 d, with no follow-up
data. That individual is not included in the summary given so
there are 12 participants in each group. While the number of
days in the study did vary from participant to participant, the
cumulative number of exposure days for the two groups were
similar, with 957 and 972 total days for the treatment and
placebo groups, respectively. A count was made of the
number of participants who reported a particular type of
adverse event at least once. The results are summarized in
Table 2, where, in addition to the counts, the percentage of
participants (out of 12) who experienced the event at least
once is given along with an exact 95% conﬁdence interval
estimate of the proportion. As shown in the table, the types of
events include cardiovascular (e.g., palpitations, nosebleeds),
central nervous system (CNS; e.g., headaches, nervousness,
insomnia, dizziness), gastrointestinal tract (GIT), infection,
allergy, appetite, malaise, or general adverse events. The last
line of Table 2 gives the number of participants who reported
any adverse event at any time. We would point out that with
the small number of participants, it is unlikely that rare
adverse events would be seen in this study.
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biochemical, and endocrine data that were not signiﬁcantly
differentbetweenthetreatmentandplacebogroups(p.0.05).
Most of the vital and physical, haematological, biochemical,
and endocrine endpoints that were measured were within the
normal physiological range and not signiﬁcantly different for
the Sutherlandia and placebo groups. These include: diastolic
and systolic blood pressure (BP), electrocardiogram (ECG),
heart rate, body temperature (oral), and weight and height;
white cell and red cell counts, haemoglobin, haematocrit,
mean corpuscular volume (MCV), and red cell diameter and
width (RCDW); neutrophil, monocyte, lymphocyte, eosino-
phil, and basophil counts; CD3, CD4, CD8 counts, and
CD4:CD8 ratio; sodium, potassium, and chloride; urea,
creatinine, and bilirubin; alkaline phosphatase, T-glutamyl
transferase, alanine transaminase, aspartate transaminase,
lactate dehydrogenase, creatine kinase, plasma glucose
(random), calcium and corrected calcium, magnesium, and
phosphorous; free thyroxine, free tri-iodothyroxine, and
TSH; and cholesterol, LDL-cholesterol, HDL-chlolesterol,
and triglycerides. No canavanine was detected in any of the
samples.
Table 4 contains the data for the six variables that were
statistically different between the treatment and placebo
groups (p , 0.05). The Sutherlandia group had a lower
respiration rate (p , 0.04), but higher platelet count (p ¼
0.03) than the placebo group. In relation to baseline values,
mean corpuscular haemoglobin (MCH; p ¼ 0.01) and mean
corpuscular haemoglobin concentration (MCHC; p ¼ 0.02)
levels were lower for the Sutherlandia compared to placebo
group.
In addition, the Sutherlandia group had higher total protein
(p ¼ 0.03) and albumin levels (p ¼ 0.03) than the placebo
group.
Note that the p-values given are for testing the signiﬁcance
of the group by post interaction term. This is equivalent to a
test for group differences in the amount of change from pre-
treatment to post-treatment. Despite these differences, all the
measurements fell within the normal physiological range for
these indices, and were of no clinical relevance.
DISCUSSION
Interpretation
This pilot study is the ﬁrst to provide scientiﬁc information
on the safety of the South African traditional medicine L.
frutescens (Sutherlandia) in healthy humans, and contribute to
establishing rigorous and ethical procedures for conducting
clinical trials on indigenous phytotherapies. Sutherlandia is
used for a variety of conditions, including those associated
with AIDS. Analysis for adverse events was done descriptively
and included: cardiovascular (palpitations, nosebleeds), CNS
(headaches, nervousness, insomnia, dizziness), GIT, infection,
allergy, appetite, malaise, or general adverse events. With the
small number of participants, which is a limitation to the
study, it is unlikely that rare adverse events would be seen.
There were no signiﬁcant differences in cardiovascular,
CNS, GIT, infection, allergy, malaise, or general adverse events
between the treatment and the placebo groups. Whilst
participants in the treatment group experienced more events
related to appetite, the constraints of the investigation related
to limited sample size precludes ﬁrm conclusions from being
drawn about these preliminary data or any speculation related
to mechanisms of action. It is nonetheless interesting to have
observed this outcome, since Sutherlandia is purported to
prevent wasting, and is in contrast to the report that cachectic
patients consuming Sutherlandia exhibited side effects such as
diarrhea, mild diuresis, dry mouth, and dizziness [12].
There were no signiﬁcant differences between the treat-
ment group and placebo group for most of the vital, physical,
haematological, biochemical, or endocrine parameters. In
adjusting for baseline values, the treatment group had higher
MCH, MCHC, platelet, total protein and albumin count, and
.......................................................................................
Table 1. Baseline Data (Mean 6 Standard Deviation) for Trial
Participants
Index Baseline
Placebo Treatment
BP systolic, mm Hg 122 (17.61) 122 (16.17)
BP diastolic, mm Hg 78 (11.48) 77 (9.20)
Pulse, b/m 70 (9.90) 74 (10.70)
ECG Normal Normal
Respiratory rate, c/m 18 (1.66) 17 (1.97)
Oral temperature, 8C 37 (0.35) 36 (0.47)
Weight, kg 68 (16.30) 67 (14.77)
Height, m 1.65 (0.08) 1.68 (0.11)
BMI, kg/m
2 25 (4.43) 24 (3.69)
Age, y 34 (8.62) 30 (5.62)
White cell count, 3 10
9/l 6.60 (1.98) 6.93 (2.61)
Red cell count, 3 10
12/l 4.44 (0.36) 4.63 (0.65)
Haemoglobin, g/dl 13.45 (1.01) 13.69 (1.24)
Haematocrit, % 39 (3.0) 40 (4.0)
MCV, fl 88.56 (4.12) 87.63 (5.78)
RCDW, % 13.37 (0.93) 13.41 (0.83)
Neutrophils, 3 10
9/l 3.85 (1.58) 4.20 (1.92)
Monocytes, 3 10
9/l 0.41 (0.12) 0.54 (0.32)
Lymphocytes, 3 10
9/l 2.13 (0.45) 1.97 (0.66)
Eosinophils, 3 10
9/l 0.18 (0.15) 0.21 (0.14)
Basophils, 3 10
9/l 0.03 (0.01) 0.02 (0.01)
CD3 count, 3 10
9/l 1,480 (380) 1,559 (467)
CD4 count, 3 10
9/l 907 (301) 930 (266)
CD8 count, 3 10
9/l 509 (149) 554 (219)
CD4:CD8 ratio 1.89 (0.67) 1.80 (0.58)
Sodium, mmol/l 140 (1.96) 140 (1.98)
Potassium, mmol/l 4.30 (0.43) 4.28 (0.37)
Chloride, mmol/l 107 (3.07) 106 (1.31)
Urea, mmol/l 3.78 (1.33) 3.47 (1.67)
Creatinine, lmol/l 71 (18.18) 72 (11.64)
Bilirubin total, mmol/l 12.25 (3.91) 12.83 (4.00)
Alkaline phosphatase, g/l 58.77 (20.74) 56.08 (12.01)
T-Glutamyl transferase, U/l 16.69 (6.61) 18.92 (11.63)
Alanine transaminase, U/l 25.85 (10.96) 22.50 (11.33)
Aspartate transaminase, U/l 23.62 (3.75) 20.92 (3.90)
Lactate dehydrogenase, U/l 451 (49.43) 427 (69.48)
Creatine kinase, lmol/l 132 (49.19) 143 (42.70)
P-Glucose (random), mmol/l 5.26 (1.04) 4.99 (0.50)
Calcium, mmol/l 2.28 (0.08) 2.30 (0.09)
Calcium (corrected), mmol/l 2.26 (0.06) 2.29 (0.05)
Magnesium, mmol/l 0.86 (0.07) 0.80 (0.10)
Phosphorus, inorganic, mmol/l 1.09 (0.18) 1.05 (0.19)
Free thyroxine, pmol/l 12.41 (1.29) 13.26 (1.67)
Free tri-iodothyrozine, pmol/l 3.51 (0.41) 3.63 (0.68)
TSH, mIU/l 1.35 (0.54) 1.13 (0.54)
Cholesterol, mmol/l 4.89 (1.30) 4.49 (0.99)
Triglycerides, mmol/l 0.72 (0.43) 0.83 (0.71)
HDL cholesterol, mmol/l 1.18 (0.30) 1.15 (0.35)
LDL cholesterol, mmol/l 3.38 (1.21) 2.97 (1.02)
doi:10.1371/journal.pctr.0020016.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
www.plosclinicaltrials.org April | 2007 | e16 0005
Clinical Trial of Lessertia frutescenslower respiration rate compared to the placebo group, but
these differences were not clinically signiﬁcant. Whilst the
latter outcome is noted, we do not have any dose-escalation
or pharmacokinetic data from this pilot study, in relation to
Sutherlandia and its effect on vital, physical, haematological,
biochemical, and endocrine indices, which is a limitation of
this investigation.
Generalizability
Sutherlandia in the amount studied (800 mg/day) is widely
advertised as being safe and is undoubtedly consumed by
many, and it was tolerated by the limited number of healthy
adults in this pilot study. Nevertheless, additional studies are
warranted to assess the safety and efﬁcacy of this and other
phytotherapies.
This study has established a precedent for the ethical and
scientiﬁcally rigorous evaluation of indigenous medicines
used by the public, and it is hoped that additional studies will
quickly follow.
Overall Evidence
Until now, no human studies have been conducted to assess
the safety or efﬁcacy of L. frutescens (Sutherlandia) with its
claimed beneﬁts ascribed to constituents including pinitol, c-
amino butyric acid (GABA), and L-canavanine [13,14]. It is
not known if these constituents work in isolation or in
unison. GABA is an inhibitory neurotransmitter present in
appreciable quantities [14], and it may potentially have
beneﬁcial effects on stress, anxiety, and depression, which
adversely affect the course of HIV disease [15]. Canavanine is
a potent L-arginine antagonist, with antiviral, antifungal,
antibacterial, and anticancer value [16–19]. Concerns have
been raised over the possible induction by canavanine of
autoimmune diseases (such as systemic lupus erythematosis),
which is thought only to occur at very high doses in
predisposed individuals or in the presence of low arginine
levels [20]. However, canavanine was not detected in the
plasma of the trial participants, perhaps because of the
dosage and its metabolism, and possible biotransformation
into another molecular entity through the P450 system, which
is affected by L. frutescens [21].
A recent Cochrane review of nine randomised placebo-
controlled trials involving 499 individuals with HIV infection
and AIDS, wherein eight different Chinese herbal medicines
were tested, was recently completed [22]. Evidence for the
effect of the eight herbal medicines identiﬁed in the review
for treatment of HIV infection and AIDS was not compelling.
Moreover, the review concluded that a need exists for larger
and more rigorously designed trials. To our knowledge, this is
the ﬁrst report of a double-blind, randomized, placebo-
controlled study assessing the safety of the African indige-
nous medicine Sutherlandia. This investigation provides a vital
step for better understanding the clinical value of traditional
phytotherapies in healthy humans. Given that this African
indigenous medicine is so extensively used [23], and is taken
.......................................................................................................................................................................................
Table 2. Counts, Percentages, Group Differences and 95% Confidence Interval Estimates of Proportion of Subjects Reporting at
Least One Adverse Event of the Type Described
Adverse Events Treatment Group Placebo Group Group Difference and CI
Count Percentage LCL UCL Count Percentage LCL UCL Percentage LCL UCL
Cardiovascular 2 0.1667 0.0209 0.4841 2 0.1667 0.0209 0.4841 0.0000  0.3643 0.3643
CNS 4 0.3333 0.0992 0.6511 6 0.5000 0.2109 0.7891  0.1667  0.5536 0.2779
GIT 6 0.5000 0.2109 0.7891 2 0.1667 0.0209 0.4841 0.3333  0.1110 0.6721
Infections 5 0.4167 0.1517 0.7233 6 0.5000 0.2109 0.7891  0.0833  0.4905 0.3531
Allergy 0 0.0000 0.0000 0.2646 0 0.0000 0.0000 0.2646 0.0000  0.2646 0.2646
Appetite 2 0.1667 0.0209 0.4841 0 0.0000 0.0000 0.2646 0.1667  0.1505 0.4841
General 0 0.0000 0.0000 0.2646 2 0.1667 0.0209 0.4841  0.1667  0.4841 0.1505
Malaise 2 0.1667 0.0209 0.4841 2 0.1667 0.0209 0.4841 0.0000  0.3643 0.3643
All 8 0.6667 0.3489 0.9008 10 0.8333 0.5159 0.9791  0.1667  0.5313 0.2428
LCL, lower confidence limit; UCL, upper confidence limit
doi:10.1371/journal.pctr.0020016.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3. Vital, Physical, Haematological, Biochemical, and
Endocrine Endpoints that Were Not Significantly Different
between the Treatment and Placebo Groups (p . 0.05), and
within the Normal Physiological Range for Humans
BP systolic and diastolic
ECG and BMI
Pulse
Oral temperature
Weight
Height
White cell count
Red cell count
Haemoglobin
Haemocrit
MCV
RCDW
Neutrophils, monocytes, lymphocytes, eosinophils, and basophils
CD3, CD4, CD8, and CD4:CD8
Sodium, potassium, and chloride
Urea, creatinine, and bilirubin
Alkaline phosphate
T-Glutamyl transferase
Alanine transaminase
Aspartate transaminase
Lactate dehydrogenase
Creatine kinase
P-Glucose (random)
Calcium and corrected calcium
Magnesium and phosphorous
Free thyroxine, free tri-iodothyrozine, and TSH
Total cholesterol, LDL-cholesterol, and HDL-cholesterol
Triglycerides
The Sutherlandia active canavanine was not detected in any participant sera.
doi:10.1371/journal.pctr.0020016.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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by many for the treatment of a variety of conditions including
those associated with HIV and AIDS, additional safety and
efﬁcacy trials are warranted in the interest of public health.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0020016.sd001 (43 KB DOC).
Trial Protocol
Found at doi:10.1371/journal.pctr.0020016.sd002 (357 KB DOC).
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Table 4. Vital, Physical, Haematological, and Biochemical Endpoints (Mean 6 Standard Deviation) that Were Significantly Different
between the Treatment and Placebo Groups (p , 0.05), and within the Normal Physiological Range for Humans
Index Baseline Month 1 Month 2 Month 3 p-Value
Placebo Treatment Placebo Treatment Placebo Treatment Placebo Treatment
Respiratory rate (c/m) 17.46 (1.66) 17.33 (1.97) 19.46 (1.66) 18.83 (2.33) 18.91 (1.04) 18.00 (1.55) 19.20 (1.03) 18.40 (1.26) 0.04
MCH (pg) 30.35 (1.56) 29.77 (2.08) 30.26 (1.70) 30.26 (1.66) 30.13 (2.04) 29.96 (1.69) 29.20 (2.00) 29.75 (1.48) 0.01
MCHC (g/dl) 34.25 (0.64) 33.93 (0.63) 34.02 (0.40) 34.37 (0.31) 33.80 (0.27) 34.11 (0.27) 33.15 (0.33) 33.42 (0.36) 0.02
Platelets (3 10
9/l) 273.00 (44.57) 244.25 (44.75) 268.00 (47.71) 269.00 (48.04) 265.00 (56.36) 272.00 (54.57) 282.00 (45.75) 274.00 (53.68) 0.03
Total protein (g/l) 72.31 (4.48) 71.92 (4.25) 71.85 (2.91) 74.92 (3.53) 71.82 (3.52) 74.10 (4.46) 72.40 (3.41) 75.50 (3.44) 0.03
Albumin (g/l) 40.77 (2.83) 39.92 (3.40) 40.38 (3.07) 41.50 (2.71) 38.36 (2.77) 39.73 (3.44) 37.70 (2.79) 40.10 (2.42) 0.03
A repeated-measures ANOVA statistical model was used to evaluate the differences between groups. Note that the p-values given are for testing the significance of the group by
postinteraction term. This is equivalent to a test for group differences in the amount of change from pre to post. Despite these differences, all the measurements fell within the normal
physiological range for these indices, and were of no clinical relevance.
doi:10.1371/journal.pctr.0020016.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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